Protease-sparing regimen in a real-life practice with naïve patients: An equal opportunity approach?

HIV Clinical Trials

Volumn 2, Issue 1, 2001, Pages 17-21

  Corales, R B ^a   Shrestha, N K ^a   Taege, A J ^a   Isada, C M ^a   Rehm, S J ^a   Schmitt, S K ^a   Gordon, S M ^a   Mawhorter, S D ^a  

^a Community Health Network ^*  (United States)

Author keywords

Efavirenz; Protease sparing regimen

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; EFAVIRENZ; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR; LAMIVUDINE; LIVER ENZYME; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PROTEINASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS ENZYME; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MALE; NONHUMAN; PRIORITY JOURNAL; REFERENCE VALUE; SERUM; T LYMPHOCYTE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS LOAD;

EID: 0035111696     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/2v0b-hdwc-agwr-h56m     Document Type: Article

References (11)

1. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
2. Update on study 006 - EFV + AZT + 3TC versus the current "standard of care" IDV + AZT + 3TC
3. Immune activation and HIV infection. Relationship to treatment and viral load
4. Correlation on CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patients infected by human immunodeficiency virus type 1
5. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multi Center AIDS Cohort Study than CD4+ cell count, soluble immune combinations of HLA-DR and CD38 expression
6. Managing HIV infection. Two new aspects
7. Clinical history of efavirenz
8. Review of NNRTIs: "Today and tomorrow"
9. Efavirenz: Practicalities, considerations and new issues
10. Cerebrospinal fluid in human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy